ESR2 and cancer: Interestingly, additional studies found that the ERβ re-expression exogenously, along with E2 treatment at 10 nM for 24 h, could be a very effective therapeutic strategy to produce anti-cancer activity for the primary colon cancer cells (SW480 and HT-29) [35,66,67].